#Opioid Market

[industryforecastnews]

Opioid Market Size, Share, Trends And Industry Outlook Report, 2030

Opioids Market Growth & Trends

The global opioid market size is expected to reach USD 25.3 billion by 2030, registering a CAGR of 1.4% during the forecast period, according to a new report by Grand View Research, Inc. Supportive regulatory policies aid manufacturers to introduce products that may contribute to the market growth. For instance, in June 2021, the U.S. FDA approved nalmefene hydrochloride injection developed by Purdue Pharma L.P.Nalmefene injectable is an opioid antagonist designed to reverse opioid overdose. The expected approval of a product is anticipated to drive the growth. 

Moreover, in June 2021, morphine sulfate tablets and morphine sulfate oral solution were approved by FDA for the management of severe pain in pediatric and adult patients for whom other treatment options were less. Thus, approval of new opioid and their launch is also expected to drive the growth. 

Growing use of the opioids for the management of post-operative pain, caused due to the surgeries, is expected to drive the market growth. According to the Canadian Centre on Substance Use and Addiction, in 2020, approximately 11.8% of all the population used opioid analgesics for the management of symptoms. Tramadol and codeine are frequently dispensed for the postoperative opioid prescription in surgeries within the region. 

Emergence of non-addictive alternative products to opioids for the pain-management leads to decline in the growth of opioid market. According to American Society of Anesthesiologists, there are several non-opioid medicines that are available over the counter steroids and NSAIDs such as aspirin, ibuprofen, and acetaminophen among others. Furthermore, wide availability and low cost associated with these drugs contribute to increase in demand for such products during the forecast period. For instance, aspirin cost USD 10 for a pack of 30 tablets. 

In addition, in February 2022, the U.S. FDA has undertaken an initiative to encourage the development of non-addictive analgesics alternatives to opioids under its HHS overdose prevention strategy for the management of acute and chronic pain. The regulatory agency issued recommendation to pharmaceutical companies to develop non-opioid analgesic products. Such initiatives may restrain the overall growth of the opioids market. 

Request a free sample copy or view report summary: https://www.grandviewresearch.com/industry-analysis/opioids-market

Opioids Market Report Highlights

By product, ER/long acting opioids segment held the largest market share in 2022 due to the increasing approval and launch of the novel ER/ long-acting opioids. For instance, in June 2021, the U.S. FDA accepted a review application for a new drug application for buprenorphine (Brixadi) for the pain management. Buprenorphine is an extended release long-acting opioid drug

By application, pain relief segment dominated the opioids market in 2022 and is expected to witness significant market growth owing to increasing prevalence of the patients with chronic pain. According to the Canadian Institute for Health Information and Canadian Pain Task Force report of 2021, 1 in every 5 adults in Canada suffers from chronic pain

By route of administration, injectable segment dominated the opioids market in 2022. This dominance can be attributed to wide availability of products used for the treatment of chronic pain and increased procedures requiring anesthesia

By distribution channel, retail pharmacy dominated the opioids market in 2022. The availability of retail pharmacies with high dispensing rate of opioid driving segment growth

Asia pacific is expected to be the fastest growing region during the forecast period. The growth of the region can be attributed to increasing geriatric population which are susceptible to the chronic pain. 

Opioids Market Segmentation

Grand View Research has segmented the global opioid market based on product, application, route of administration, distribution channel, and region:

Opioids Product Outlook (Revenue, USD Million, 2018 - 2030)

IR/Short Acting Opioids

ER/Long-Acting Opioids

Opioids Application Outlook (Revenue, USD Million, 2018 - 2030)

Pain relief

Anesthesia

Cough suppression

Diarrhea suppression

De-addiction

Opioids Route of administration Outlook (Revenue, USD Million, 2018 - 2030)

Oral

Injectable

Others

Opioids Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

Hospital pharmacy

Retail Pharmacy

Others

Opioids Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

Europe

Asia Pacific

Latin America

Middle East and Africa

List of Key Players in the Opioids Market

Purdue Pharma L.P.

Johnson & Johnson Services, Inc.

Hikma Pharmaceuticals PLC

Pfizer, Inc.

AbbVie Inc.

Sanofi

Sun Pharmaceutical Industries Ltd

Grünenthal

Browse Full Report: https://www.grandviewresearch.com/industry-analysis/opioids-market

[vautour-coccinelle-serpent]

spent a good chunk of time reading about VX-548 and I still can't tell whether it's going somewhere

[one-winged-dreams]

I'm definitely going to have to add Wedge as a platonic after that dream I just had.

[marketsndata]

[soumyafwr]

Non-opioid Pain Treatment Market Size, Overview, Share and Forecast 2031

[blog-site-for-market-research]

Opioids Market Global Industry Analysis and Forecast (2023-2032)

Market Overview –

The opioids market is predicted to grow at a 5.4% CAGR between 2023 and 2032, reaching USD 6.93 billion.

The Opioids Market encompasses pharmaceutical drugs derived from opium or synthesized to mimic its effects, primarily used for pain management. Opioids are potent analgesics commonly prescribed for acute and chronic pain conditions, including postoperative pain, cancer-related pain, and severe injuries. However, the widespread use of opioids has led to concerns about addiction, overdose, and misuse.

The opioids market, while grappling with addiction concerns, sees a promising trend with the growing adoption of naltrexone. This medication offers a novel approach to managing opioid dependence by blocking opioid receptors, reducing cravings and withdrawal symptoms. As awareness rises, naltrexone's role in addiction treatment strengthens, contributing to a multifaceted approach to opioid management.

In recent years, the opioids market has witnessed significant growth globally due to several factors. Firstly, there has been increasing recognition of the need for effective pain management options, particularly in the context of aging populations and rising prevalence of chronic pain conditions. Key players in this market include pharmaceutical companies, healthcare providers, pain management clinics, and regulatory agencies, collaborating to develop and distribute opioids responsibly while mitigating risks of abuse and addiction.

Moreover, advancements in opioid formulations and delivery systems have led to the development of extended-release, abuse-deterrent, and non-opioid combination products. These innovations aim to improve pain control, reduce side effects, and minimize the potential for addiction and misuse.

Segment analysis

The segment study for the global opioids market is done by product, end-users, and applications. The product based segments of the opioids market are immediate-release/short-acting opioids and extended-release/long-acting opioids. The sub-segments of the extended-release opioid segment are morphine, oxycodone, oxymorphone, and hydromorphone among others. The extended-release opioid segment can value above USD 12,750.91 Mn by 2027. The sub-segments of the immediate-release opioid segment are hydrocodone, codeine, morphine, and fentanyl among others. The application-based segments of the opioids market are anesthesia, pain relief, diarrhoea suppression, cough suppression, and de-addiction. The end-user based segments of the global opioids market are pharmacies, academic research institutes, and hospitals & clinics. The end-user segments can largely benefit the opioids market.

Regional Analysis

The opioids market in Americas can secure the largest share of the worldwide global opioids market in the study period. The increase in the application of intravenous usage of opioids due to its fast action can promote the regional market rise in the near future. The growing awareness of IV application of opioids and its medical uses can drive the regional market in the near future. The market in Americas can accounted for the major share of the worldwide opioids market owing due rise in intravenous drug application. In Europe, the opioids market can thrive owing to the rise in demand for palliative care facilities. The introduction of reformed regulations for prescribing opioids can promote the market in the region. In Asia Pacific, the market is likely to be fast growing through the review period. Populace demographics and rise in availability of effective opioid medicines can favor the Asia Pacific opioids market in the analysis period. In South Korea, the market can secure about 6% of the APAC opioids market by 2027. In the Middle East and Africa region, a steady rise for the market is likely due to increase in count of opioid manufacturers in the region.

Key Players –

Opioids key players include Sanofi from France, Teva Pharmaceutical Industries from Israel, Bristol-Myers Squibb from the US, AbbVie Inc. from the US, Boehringer Ingelheim International GmbH from Germany, Purdue Pharma from the US, Astellas Pharma Inc. from Japan, Pfizer Inc. from the US, Biogen Idec from the US, Bayer from Germany, and GlaxoSmithKline from the UK.

Related Reports –

amniotic membrane market

asia pacific aesthetics market

diabetic nephropathy market

chronic kidney disease market

For more information visit at MarketResearchFuture

[pharmanucleus1]

Global Opioid Use Disorder Market: Navigating the Insights and Innovations

Opioid Use Disorder Market 

KEY MARKET INSIGHTS 

The global Opioid Use Disorder (OUD) Market size was valued at USD 2.88 billion in 2023 and is projected to grow from USD 3.11 billion in 2022 to USD 5.64 billion by 2030, exhibiting a CAGR of 8.9% during the forecast period. Based on our analysis, the global market exhibited a decline of -10.1% in 2020 as compared to 2019. The global COVID-19 pandemic has been unprecedented and staggering, with opioid use disorder experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels.

Click here for full report:

https://www.pharmanucleus.com/reports/opioid-use-disorder 

Opioid Use condition (OUD) is a complicated condition characterised by the compelling use of opioid medicines, even if the individual wishes to quit or if the drugs significantly impact the person's mental and physical well-being. Buprenorphine, methadone, and naltrexone are the three pharmacological groups used in the pharmaceutical therapy. These are the only drug classes authorised by the FDA in the United States. 

The number of prescriptions for painkillers, which commonly contain opioids, is expected to climb as the worldwide population of individuals suffering from chronic pain grows. When these opioid-based medications are used and the patient's suffering is relieved, the patient's reliance or addiction to these drugs rises. This addiction is dangerous since an opioid overdose can result in death or lifelong impairment of a person's normal psychological and physiological functioning. 

Several governments, like the United States, have put laws in place to successfully handle this condition in order to lessen the risk. These legislative reforms, together with the increasing number of product releases by big corporations, are expected to have a positive influence on the sector. 

Click here for sample request:

https://www.pharmanucleus.com/request-sample/1182

POST COVID-19 IMPACT 

Reduced Demand for Medications amid COVID-19 Pandemic to Negatively Impact Market Growth? 

Depending on the demand, the COVID-19 pandemic had both beneficial and bad effects on pharmaceutical firms. Certain pharmaceutical items saw a drop in demand as fewer individuals risked visiting healthcare institutions such as hospitals and clinics. To stop the spread of the coronavirus epidemic, the different governments ordered strict national lockdowns. As a consequence, patient visits to hospitals decreased dramatically. Non-essential medical services cancellation or delay impacted market development as well. 

On the other side, there was a noticeable increase in patients having opioid overdoses and relapses in the OUD market. However, well-known firms in the field, such as Indivior, saw a significant drop in product sales during this time. Sales continued to fall sharply as a result of Covid-19-related problems. As a result, the worldwide market saw a negative trend during the epidemic. 

Click here for full report:

https://www.pharmanucleus.com/reports/opioid-use-disorder

LATEST TRENDS 

Increasing Consideration of Buprenorphine Patches as an Effective Treatment Mode to Propel Market Growth 

The industry has lately seen an increase in the demand for buprenorphine treatment patches. These patches are regarded as an effective medication for the treatment of opioid use disorders. The numerous advantages associated with transdermal patches, such as ease of medication delivery and decreased discomfort, are customary and self-administered. Furthermore, these transdermal patches may be a viable option for individuals requiring round-the-clock opioid medication for opioid use disorder. 

In 2019, for example, WellSpan Health collaborated with York Opioid Collaborative to conduct a clinical study to develop a Lidocaine patch for the treatment of OUD. During the projected period, such collaboration is expected to boost treatment uptake. Furthermore, increased patient participation is expected to drive worldwide Opioid Use Disorder (OUD) market growth throughout the forecast period. 

DRIVING FACTORS 

Growing Opioid Addiction Cases to Augment the OUD Market Share? 

The worldwide population is today suffering from a variety of severe and chronic ailments, including pain, cancer, cardiovascular disease, and other problems. To treat these problems, painkillers, particularly opioids, are used. Drug usage frequently leads to drug addiction in the patient. The patient is expected to have drug withdrawal symptoms as a result of their increasing reliance on these drugs and their sudden discontinuation. 

According to the National Drug Dependence Treatment Centre's (NDDTC) Magnitude of Substance Use in India report published in February 2019, the prevalence of current opioid use is 2.06%, and approximately 0.55% of Indians are expected to require help for opioid use problems (harmful use and dependence). 

On account of these factors, the likelihood that patients will experience tragic outcomes, such as death induced by an opioid overdose, rises. 

Growing Focus of Government & Non-government Institutions to Support Expansion 

Another major driving reason driving market development is the growing involvement of governmental and non-governmental organisations in raising awareness about opioid overdose and associated consequences. The number of opioid addicts has substantially grown, prompting various organisations to take a more comprehensive strategy to combating the problem. Numerous countries have increased their efforts to support patients and reduce the effects of opioid addiction. 

For example, in March 2022, the Department of Health and Human Services (HHS) announced financing for substance use treatment and prevention programmes in order to increase access to medication-assisted treatment for opioid use disorder and prevent prescription drug misuse. 

Similarly, similar programmes are expected to encourage more people suffering from opioid addiction to seek treatment. These factors are expected to have a positive impact on the worldwide market throughout the forecast period. 

RESTRAINING FACTORS 

Adverse Effects of OUD Drugs to Restrain Market Growth? 

The adverse effects of the medications used to treat opioid addiction are expected to stymie the market throughout the projected period. 

These medicines commonly cause muscular pains, vomiting, diarrhoea, bone/joint pain, respiratory difficulties, bladder discomfort, constipation, and stomach cramps. Furthermore, in severe situations of adverse medication response, the patient may suffer from depression and other psychological issues. 

The hazards connected with these pharmaceuticals have resulted in a warning from the US Food and Drug Administration, which has a negative influence on the drug class, lowering the adoption of medications in this form of treatment. 

For instance, in January 2022, the U.S. FDA warned about dental problems with buprenorphine medicines dissolved in the mouth to treat OUD and pain. Dental issues, including oral infections, cavities, tooth decay, and teeth loss can be serious and have been reported even in patients with no history of dental issues. 

Such factors might hamper the market growth during the forecast period to a certain extent. 

[meghanester]

Opioid Dependence Treatment Market to Expand at a Stunning CAGR of ~9% Assessment | Segments, Expansion, Demand, and Opportunities During 2023-2035

Global Opioid Dependence Treatment Market Key Insights 

During the forecast period of 2023-2035, the global opioid dependence treatment market is expected to reach an estimated value of ~USD 7 billion by 2035, by expanding at a CAGR of ~9%. The market further generated a revenue of ~USD 3 billion in the year 2022. Major key factors propelling the growth of opioid dependence treatment market worldwide are the growing cases of opioid abuse, and addiction of individuals on illegal opioid drugs all across the globe.

Market Definition of Opioid Dependence Treatment

Aspects of opioid dependency and opioid use disorders are combined in opioid dependence. Many different locations and pharmacological and behavioral treatment modalities are employed to treat opioid drug addiction. Most currently being utilized treatments focus on maintenance therapy using buprenorphine, an opioid agonist, together with methadone, naltrexone, or an opioid antagonist. As a rescue medication in the case of an overdose, buprenorphine is occasionally used with naloxone in rare circumstances.

Get a Sample PDF Brochure: https://www.researchnester.com/sample-request-4003

Global Opioid Dependence Treatment Market: Growth Drivers 

The growth of the global opioid dependence treatment market can majorly be attributed to the growing consumption of opioid drugs, which could further cause opioid use disorder among people. Opioid use disorder (OUD) has affected 3 million US residents and 16 million other people worldwide. Further, in the United States, about 500,000 people are addicted to heroin. Opioid addiction is a chronic disease that could have serious negative effects on one's health, relationships, and finances. Opioids are a group of medications that work on the neurological system to relieve pain and elicit a sense of euphoria. Hence, growth in the number of people suffering from chronic illnesses is also expected to consume opioid drugs further boosting the growth of the market. For instance, nearly half of all Americans—roughly 45%, or 133 million people—suffer from at least one chronic illness, and the number is rising. However, despite being often used for therapeutic purposes, opioid medicines carry the risk of abuse, dependency, and other health issues if used excessively or without supervision. For instance, according to the World Health Organization, drug use is responsible for 0.5 million fatalities globally. Overdose is the primary cause of nearly 30% of these deaths, which have an opioid connection in excess of 70%. Hence this factor is expected to boost the growth of the market in coming years.

The global opioid dependence treatment market is also estimated to grow majorly on account of the following: 

Growing Government Initiatives to Tackle Opioid Dependence Treatment Effectively

Surge in Consideration of Buprenorphine Patches

Increasing Engagement of Non-Government Organization

Request for customization @ https://www.researchnester.com/customized-reports-4003

Global Opioid Dependence Treatment Market: Restraining Factor 

The side effects that could result from the medications used to treat opioid addiction are one of the most important restraints that are projected to restrict the expansion of the global market over the forecast period. Vomiting, bladder pain, abdominal cramps, diarrhoea, respiratory problems, bone/joint pain, muscular aches, and constipation are just a few of the common side effects from these medications. Additionally, in very severe circumstances of adverse effects, the patient may also experience psychological issues including depression. In some instances, using SUBOXONE to treat opioid dependence might cause hyperventilation and a fast or irregular heartbeat. Thus, it is anticipated that during the projection period, these medications' negative effects would impede market expansion.

Global Opioid Dependence Treatment Market Segmentation 

By Drug Class (Naloxone, Buprenorphine, and Methadone)

The buprenorphine segment is anticipated to hold the largest market share over the forecast period. The growth of this segment could be attributed to the growing usage of buprenorphine for opioid use disorder. Buprenorphine is a medicine licensed by the Food and Drug Administration (FDA) as a medication-assisted treatment (MAT) for Opioid Use Disorder (OUD). However, overdose of buprenorphine could cause adverse effect on health. In the past few years, it has been observed that the misuse of buprenorphine was on the rise, mostly among heroin users. The high opioid abuse in order to treat pain, manage psychiatric disorders, get high, manage withdrawal symptoms, and more, further lead to high consumption of buprenorphine as to wean themselves off opioids. However, prevalence of Buprenorphine abuse among adults with OUD decreased from 2015 to 2019. In 2019, approximately 2.4 million US individuals used buprenorphine, and close to 0.7 million abused it, compared to approximately 4.9 million and about 3.0 million in previous years, respectively, who misused hydrocodone and oxycodone.

By Sales Channel (Retail Pharmacies, Online Pharmacies, Hospitals, and Rehabilitation Centers)

By Region

The North America opioid dependence treatment market is anticipated to hold the largest market share by the end of 2035 among the market in all the other regions, backed by rising awareness among general population about opioid use disorder, and growth in patient pool in the region. According to a survey conducted in 2019 by the U.S. Department of Health and Human Services, 10.1 million adults aged 12 and older abused opioids in 2018, compared to 9.7 million adults who misused prescription painkillers.

The market research report on global opioid dependence treatment also includes the market size, market revenue, Y-o-Y growth, and key player analysis applicable for the market in North America (U.S., and Canada), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC (Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), and Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa). 

Key Market Players Featured in the Global Opioid Dependence Treatment Market 

Some of the key players of the global opioid dependence treatment market are Orexo AB, Indivior PLC, Titan Pharmaceuticals, Inc., Viatris Inc., Pfizer, Inc., Hikma Pharmaceuticals PLC, BioDelivery Sciences International Inc., Teva Pharmaceutical Industries Ltd., Alkermes, Camurus AB, and others.

Obtain this Report @ https://www.researchnester.com/reports/opioid-dependence-treatment-market/4003

About Research Nester 

Research Nester, which is a leading service provider for strategic market research and consulting services, aims to provide unbiased, unparalleled market insights and industry analysis. These analyses help conglomerates, executives, and industries to take wise decisions for their businesses as well as for their future marketing strategy, expansion and investment among others. We believe that our expertise in the field of market research can help businesses to expand to its new horizon. Our team of research analysts can provide businesses a right guidance at the right time, while our out of box thinking helps our clients to take wise decision in order to avoid future uncertainties. 

Contact for more Info: 

AJ Daniel 

Email: info@researchnester.com 

U.S. Phone: +1 646 586 9123  

U.K. Phone: +44 203 608 5919 

[mostlysignssomeportents]

MLMs are the mirror-world version of community organizing

If you'd like an essay-formatted version of this post to read or share, here's a link to it on pluralistic.net, my surveillance-free, ad-free, tracker-free blog:

https://pluralistic.net/2025/02/05/power-of-positive-thinking/#the-socialism-of-fools

In her unmissable 2023 book Doppelganger, Naomi Klein paints a picture of a "mirror world" of right wing and conspiratorial beliefs that are warped, false reflections of real crises:

https://pluralistic.net/2023/09/05/not-that-naomi/#if-the-naomi-be-klein-youre-doing-just-fine

For example, Qanon's obsession with "child trafficking" is a mirror-world version of the real crises of child poverty, child labor, border family separations and kids in cages. Anti-vax is the mirror-world version of the true story of the Sacklers and their fellow opioid barons making billions on Oxy and fent, with the collusion of corrupt FDA officials and a pliant bankruptcy court system. Xenophobic panic about "immigrants stealing jobs" is the mirror world version of the well-documented fact that big business shipped jobs to low-waged territories abroad, weakening US labor and smashing US unions. Cryptocurrency talk about "decentralization" is the mirror-world version of the decay of every industry (including tech) into a monopoly or a cartel.

Klein is at pains to point out that other political thinkers have described this phenomenon. Back in the 19th century, leftists called antisemitism "the socialism of fools." Socialism – the idea that working people are preyed upon by capital – is reflected in the warped mirror as "working people are preyed upon by international Jewish bankers."

The mirror world is a critical concept, because it shows that far right and conspiratorial beliefs are often uneasy neighbors with real, serious political movements. The swivel-eyed loons have a point, in other words:

https://locusmag.com/2023/05/commentary-cory-doctorow-the-swivel-eyed-loons-have-a-point/

Once you understand the mirror world, you start to realize that many right wing conspiracists could have been directed into productive movements, if only they'd understood that their problems were with systems, not sinister individuals (this is why Trump has ordered a purge of any federally funded research that contains the word "systemic"):

https://mamot.fr/@Lazarou@mastodon.social/113943287435897828

This also explains why the "tropes" of right wing conspiratorialism sometimes echo left wing, radical thought. I once had a (genuinely unhinged) dialog with a self-described German "progressive" who told me that criticizing the finance industry as parasitic on the real economy was "structurally antisemitic." Nonsense like this is why Klein's "mirror world" is so important: unless you understand the mirror world, you can end up believing that "progressive" just means "defending anything the right hates."

Historian Erik Baker is the author of a new book, Make Your Own Job: How the Entrepreneurial Work Ethic Exhausted America, which has some very interesting things to say about the mirror world:

https://www.hup.harvard.edu/books/9780674293601

In a recent edition of the always-excellent Know Your Enemy podcast, the hosts interviewed Baker about the book, and the conversation turned to the subject of pyramid schemes, the "multilevel marketing systems" that are woven into so many religious, right-wing movements:

https://www.dissentmagazine.org/blog/know-your-enemy-the-entrepreneurial-ethic/

MLMs have it all: prosperity gospel ("God rewards virtue with wealth"), atomization ("you are an entrepreneur and everyone in your life is your potential customer"), and rabid anti-Communism ("solidarity is a trick to make you poorer").

The rise of the far right can't be separated from the history of MLMs. The modern MLM starts with Amway, a cultlike national scam that was founded by Jay Van Andel and Richard DeVos (father-in-law of Betsy DeVos).

Rank-and-file members of the Amway cult lived in dire poverty, convinced that their financial predicament was their own fault for not faithfully following the "sure-fire" Amway method for building a business. Andrea Pitzer's gripping memoir of growing up in an Amway household offers a glimpse of the human cost of the cult:

https://www.theatlantic.com/ideas/archive/2025/01/amway-america/681479/?gift=j9r7avb6p-KY8zdjhsiSZxYkntna5M_rYEv4707Zqqs

Amway – and MLMs like it – don't just bleed out their members by convincing them to buy mountains of useless crap they're supposed to sell to their families, while enriching the people at the top of the pyramid who sell it to them. The "toxic positivity" of multi-level marketing cults forces members deep into debt to pay for seminars and retreats where they are supposed to learn how to repair the personal defects that keep them from being "successful entrepreneurs." The topline of the cult isn't just getting rich selling stuff – they're making bank by selling false hope, literally, in Hilton ballrooms and convention centers across the country, where hearing an MLM scammer berate you for being a "bad entrepreneur" costs thousands of dollars.

Amway destroyed so many lives that Richard Nixon's FTC decided to investigate it. The investigation wasn't going well for Amway, which was facing an existential crisis that they were rescued from by Nixon's resignation. You see, Nixon's successor, Gerald Ford, was the former Congressman of Amway co-founder Jay Van Andel, who was also the head of the US Chamber of Commerce, the most powerful business lobbyist in America.

At Ford's direction, the FTC exonerated Amway of all wrongdoing. But it's even worse than that: Ford's FTC actually crafted a rule that differentiated legal pyramid schemes from illegal ones, based on Amway's destructive business practices. Under this new rule, any pyramid scheme that had the same structure as Amway was presumptively legal. Every MLM operating in America today is built on the Amway model, taking advantage of the FTC's Amway rule to operate in the open, without fear of legal repercussions.

MLMs prey on the poor and desperate: women, people of color, people in dying small towns and decaying rustbelt cities. It's not just that these people are desperate – it's that they only survive through networks of mutual aid. Poor women rely on other poor women to help with child care, marginalized people rely on one another for help with home maintenance, small loans, a place to crash after an eviction, or a place to park the RV you're living out of.

In other words, people who lack monetary capital must rely on social capital for survival. That's why MLMs target these people: an MLM is a system for destructively transforming social capital into monetary capital. MLMs exhort their members to mine their social relationships for "leads" and "customers" and to use the language of social solidarity ("women helping women") to wheedle, guilt, and arm-twist people from your mutual aid network into buying things they don't need and can't afford.

But it's worse, because what MLMs really sell is MLMs. The real purpose of an MLM sales call is to convince the "customer" to become an MLM salesperson, who owes you a share of every sale they make and is incentivized to buy stock they don't need (from you) in order to make quotas. And of course, their real job is to sign up other salespeople to work under them, and so on.

An MLM isn't just a pathogen, in other words – it's a contagion. When someone in your social support network gets the MLM disease, they don't just burn all their social ties with you and the people you rely on – they convince more people in your social group to do the same.

Which brings me back to the mirror world, and Erik Baker's conversation with the Know Your Enemy podcast. Baker starts to talk about who gets big into Amway: "people who already effectively lead by the force of their charisma and personality many other people in their lives. Right? Because you're able to sell to those people, and you're able to recruit those people. What are we talking about? Well, they're effectively recruiting organizers, people who have a natural capacity for organizing and then sending them out in the world to organize on behalf of Christian capitalism."

Listening to this, I was thunderstruck: MLM recruiters are the mirror world version of union organizers. In her memoir of growing up in Amway, Andrea Pitzer talks about how her mom would approach strangers and try to lead them through a kind of structured discussion:

Everywhere we went—the mall, state parks, grocery stores—she’d ask people whether they could use a little more money each month. “I’d love to set up a time to talk to you about an exciting business opportunity.” The words should have seemed suspect. Yet people almost always gave her their number. Her confidence and professionalism were reassuring, and her enthusiasm was electric, even, at first, to me. “What would you do with $1 million?” she’d ask, spinning me around the kitchen.

This kind of person, having this kind of dialog, is exactly how union organizers work. In A Collective Bargain, Jane McAlevey's classic book on labor organizing, she describes how she would seek out the charismatic, outgoing workers in a job-site, the natural leaders, and recruit them to help bring the other workers onboard:

https://pluralistic.net/2023/04/23/a-collective-bargain/

Organizer training focuses on how to have a "structured organizing conversation," which McAlevey described in a 2019 Jacobin article:

“If you had a magic wand and could change three things about life in America [or her town or city or school], what would you change?” The rest of your conversation needs to be anchored to her answers to that question.

https://jacobin.com/2019/11/thanksgiving-organizing-activism-friends-family-conversation-presidential-election

The MLM conversation and the union conversation have eerily similar structures, but the former is designed to commodify and destroy solidarity, and the latter is designed to reinforce and mobilize solidarity. Seen in this light, an MLM is a mirror world union, one that converts solidarity into misery and powerlessness instead of joy and strength.

The MLM movement doesn't just make men like Rich De Vos and Jay Van Andel into billionaires. MLM bosses are heavy funders of the right, a blank check for the Heritage Foundation. Trump is the MLM president, a grifter who grew up on the gospel of Norman Vincent Peale – a key figure in MLM cult dynamics – who tells his followers that wealth is a sign of virtue. Trump boasts about all the people he's ripped off, boasting about how getting away with cheating "makes me smart":

https://pluralistic.net/2024/12/04/its-not-a-lie/#its-a-premature-truth

The corollary is that being cheated means you're stupid. Caveat emptor, the motto of the cryptocurrency industry ("not your wallet, not your coins") that spent hundreds of millions to get Trump elected.

Tech has its own mirror world. The people who used tech to find fellow weirdos and make delightful and wonderful things are mirrored by the people who used tech to find fellow weirdos and call for fascism, ethnic cleansing, and concentration camps.

In Picks and Shovels, my next novel (Feb 17), I introduce readers to a fictitious 1980s religious computer sales cult called Fidelity Computing, run by an orthodox rabbi, a Catholic priest and a Mormon rabbi:

https://us.macmillan.com/books/9781250865908/picksandshovels

Fidelity is a faith scam, a pyramid scheme that is parasitic upon the bonds of faith and fellowship. Martin Hench, the hero of the story – a hard-fighting high tech forensic accountant – goes to work for a competing business, Computing Freedom, run by three Fidelity ex-employees who have left their faiths and their employers to pursue a vision of computers that is about liberation, rather than control.

The women of Computing Freedom – a queer orthodox woman who's been kicked out of her family, a Mormon woman who's renounced the LDS over its opposition to the Equal Rights Amendment, and a nun who's left her order to throw in with the Liberation Theology movement – are all charismatic, energetic, inspirational organizers.

Because of course they are – that's why they were so good at selling computers for the Reverend Sirs who sit at the top of Fidelity Computing's pyramid scheme.

Hearing Baker's interview and reading Pitzer's memoir last week made it all click together for me. Not just that MLMs destroy social bonds, but that within every person who gets sucked into an MLM, there's a community organizer who could be building the bonds that MLMs destroy.

[versatile-blogger-1]

U.S. Opioids Market Is Estimated To Witness High Growth Owing To Increasing Prevalence Of Chronic Pain

Market Overview: The U.S. Opioids Market offers a range of pharmaceutical products that are used to manage and treat chronic pain. Opioids are highly effective in relieving moderate to severe pain, making them essential for patients suffering from conditions such as cancer, post-surgical pain, and chronic musculoskeletal pain. The market provides a variety of opioids, including extended-release formulations that provide long-lasting pain relief. The advantages of opioids include their ability to alleviate pain and improve the quality of life for patients with chronic pain conditions. The need for these products is driven by the increasing prevalence of chronic pain across the United States. Market Key Trends: One key trend in the U.S. Opioids Market is the growing adoption of abuse-deterrent formulations. Due to the addictive nature of opioids, there has been a rise in the misuse and abuse of these drugs. To address this issue, pharmaceutical companies have developed abuse-deterrent formulations that make it harder for individuals to manipulate the drug for non-medical purposes, such as crushing or dissolving it. These formulations incorporate physical or chemical barriers that prevent abuse and discourage tampering. The adoption of abuse-deterrent formulations is expected to increase, driven by regulatory initiatives and healthcare provider awareness about the risks associated with opioid misuse. The global U.S. Opioids Market Growth is estimated to be valued at US$16,285.2 million in 2022 and is expected to exhibit a CAGR of 5.5% over the forecast period 2022-2030, as highlighted in a new report published by Coherent Market Insights. PEST Analysis: Political: The political landscape plays a significant role in the U.S. opioids market. Government regulations and policies addressing drug usage and prescription are crucial factors that impact the market. These regulations aim to control the opioid crisis, reducing the misuse and addiction associated with these drugs. Economic: The economic factors influencing the U.S. opioids market include healthcare expenditure, insurance coverage, and the overall economic condition of the country. Economic growth and stability can contribute to increased healthcare spending, leading to higher demand for opioids. Social: The social aspect of the U.S. opioids market revolves around the societal perception of pain management and the use of opioids. Public awareness campaigns and education regarding addiction and overdose risks have influenced social attitudes towards opioids, leading to increased caution and a decline in opioid prescriptions. Technological: Technological advancements such as pain management devices, drug delivery systems, and digital health solutions are transforming the U.S. opioids market. These innovations enhance the efficacy of pain management while minimizing the risks associated with opioids. Key Takeaways: The U.S. opioids market is expected to witness high growth, exhibiting a CAGR of 5.5% over the forecast period from 2022 to 2030. The market is driven by increasing cases of chronic pain, the aging population, and the growing prevalence of conditions requiring palliative care. Furthermore, the rising awareness about pain management and the introduction of advanced technologies are also contributing to market growth. Regionally, the United States dominates the opioids market due to its well-established healthcare infrastructure, high healthcare expenditure, and the prevalence of chronic pain conditions. The country is at the forefront of developing regulations to control the opioid crisis, leading to a decline in opioid prescriptions and increased focus on alternative pain management approaches.

[cmibloggers]

Global Opioids Agonist Drugs Market Is Estimated To Witness High Growth Owing To Increasing Use of Opioids for Pain Management

The global Opioids Agonist Drugs market is estimated to be valued at US$ 17,132.5 million in 2015 and is expected to exhibit a CAGR of 4.2% over the forecast period, as highlighted in a new report published by Coherent Market Insights.

A) Market Overview: Opioids agonist drugs are a class of medications primarily used for pain management. They act on the opioid receptors in the brain and spinal cord to reduce the perception of pain. Opioids are highly effective in managing moderate to severe pain in conditions such as cancer, trauma, and post-surgical pain. The advantage of opioids agonist drugs lies in their ability to provide significant pain relief, improving the quality of life for patients suffering from chronic pain.

B) Market Key Trends: One key trend in the Opioids Agonist Drugs Market is the increasing use of opioids for pain management. Chronic pain affects a significant portion of the global population, and opioids are often the go-to choice for managing such pain. The rise in chronic diseases, such as cancer, arthritis, and neurological disorders, has further fueled the demand for opioids agonist drugs. For example, according to the World Health Organization, it is estimated that over 382 million people globally suffer from diabetes, a condition that often leads to neuropathic pain requiring opioid-based pain management.

C) Pest Analysis: - Political: Governments worldwide have tightened regulations on opioid prescriptions due to concerns over misuse, addiction, and overdose. This has led to stricter control over opioid distribution and increased scrutiny over healthcare providers prescribing opioids. - Economic: The growing incidence of chronic diseases and an aging population have contributed to the increased demand for opioids agonist drugs. Additionally, the economic burden of chronic pain on healthcare systems has prompted investments in effective pain management solutions. - Social: The stigma associated with opioids and the rising awareness about addiction and abuse have led to greater caution among healthcare providers in prescribing opioids. Additionally, there is a growing demand for safer alternatives to opioids for pain management. - Technological: Advancements in drug delivery systems, such as transdermal patches and extended-release formulations, have improved the efficacy and safety profile of opioids agonist drugs. Furthermore, telemedicine and remote patient monitoring technologies have facilitated better pain management for patients in remote areas.

D) Key Takeaways: - Market size: The global opioids agonist drugs market is expected to witness high growth, exhibiting a CAGR of 4.2% over the forecast period, due to increasing use of opioids for pain management. - Regional analysis: North America is the fastest-growing and dominating region in the opioids agonist drugs market, attributed to the higher prevalence of chronic pain conditions and favorable reimbursement policies. - Key players: Key players operating in the global opioids agonist drugs market include Pfizer Inc., Purdue Pharma, Boehringer Ingelheim, Janssen Pharmaceuticals, Inc., Actavis Plc., Sanofi, Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Egalet Corporation, and Endo Pharmaceuticals Inc. These companies focus on research and development activities to introduce innovative products and maintain their market position. In conclusion, the global opioids agonist drugs market is expected to witness significant growth in the coming years driven by the increasing use of opioids for pain management. However, strict regulations and the need for safer alternatives present challenges for the market players. Nonetheless, advancements in drug delivery systems and technology offer opportunities for market expansion.

[marketspace360]

Opioids Market Expected to Witness High Growth over the Forecast Period 2022-2029

[soumyafwr]

https://www.cienciared.es/blogs/226416/Non-opioid-Pain-Treatment-Market-Size-Overview-Share-and-Forecast

Non-opioid Pain Treatment Market Size, Overview, Share and Forecast 2031

[covid-safer-hotties]

Deaths Are Up Post-Covid, and So Are Funeral Stocks: Prognosis - Published Aug 19, 2024

The Business of Death Aussies, Americans, and Brits — and no doubt people in many other nations — are dying faster than before the pandemic.

Even though Covid waves are becoming less deadly, thanks mostly to increased immune protection from vaccinations and prior infections, the coronavirus remains a significant killer. And stubbornly high all-cause mortality rates indicate that its direct and indirect effects are helping drive a sustained increase in death and disease around the globe.

It’s depressing news, I know.

With death comes bereavement, and there’s been a lot of that since SARS-CoV-2 began spreading widely in late 2019. The number of officially reported Covid fatalities (7.1 million worldwide) doesn’t fully explain the trend in excess deaths. (Neither do Covid vaccines, since body bags were piling up months before the shots were released, and multiple studies show the immunizations protect against severe illness and death).

There’s no silver lining to the tragic loss of life. But if one group sees an upside, it’s those providing funerals, cremations, and burials. Publicly traded companies handling funerals and related services have handed investors an average 79% return since Jan. 1, 2020 — outpacing the 60% gain in the MSCI All Country World Index, one of the broadest measures of the global equity market.

The US highlights the morbid picture. In the two decades before the pandemic, the number of deaths had been climbing at an average clip of almost 1% a year — reflecting population growth and aging, and the devastating opioid epidemic — for a crude rate in 2019 of 869.7 deaths for every 100,000 Americans.

Covid catapulted the rate well beyond 1,000 in 2020 and 2021 before the rate dropped back to just over 984 in 2022. Last year, there were 927.4 deaths per 100,000 people in the US — almost 12% above the 20-year average — for nearly 3.1 million deaths all up.

The coronavirus directly and indirectly contributed to many of them. For instance, a jump in drug overdoses and alcohol use–related diseases during the pandemic likely added to fatalities from unintentional injuries and chronic liver disease in 2023, according to a study this month. Covid also led to more cardiometabolic disease, and age-adjusted mortality rates for diabetes, heart disease, and stroke were above pre-pandemic levels.

Last month, researchers reported similar findings in Australia, where emergency departments have taken longer to hospitalize patients arriving in ambulances — a sign of health-system stress associated with a greater risk of patients dying up to 30 days after their initial medical encounter.

Mortality rates in England have also stayed persistently high since Covid hit, likely reflecting the direct effects of the illness, pressures on the National Health Service, and disruptions to chronic disease detection and management, researchers said in a study in January.

“The greatest numbers of excess deaths in the acute phase of the pandemic were in older adults,” Jonny Pearson-Stuttard and colleagues wrote. “The pattern now is one of persisting excess deaths, which are most prominent in relative terms in middle-aged and younger adults.”

Almost five years into the pandemic, dodging SARS-CoV-2 still remains one of the best ways to avoid adding to the toll — and the frequency of funerals. —Jason Gale